公开(公告)号：EP4260851A1

公开(公告)日：2023-10-18

申请号：EP21903486.5

申请日：2021-12-10

申请人： Kinki University ,  Yashiro Co., Ltd. ,  OSAKA UNIVERSITY

发明人： ZAIMA Nobuhiro ,  KUGO Hirona ,  KITANO Motohiro ,  HIROTA Yoshinori ,  HIRANO Ken-ichi

IPC分类号： A61K31/19 ,  A23L33/12 ,  A61K31/22 ,  A61P9/00

摘要： An aortic aneurysm has few noticeable symptoms and is at high risk of rupture without a sign of abnormality. Further, if the aortic aneurysm ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing and treating an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, continuous intake of the composition can not only inhibit the progression of the aortic aneurysm but also mediate the regression of the aortic aneurysm, thereby producing the effect of improving vital prognosis.

公开(公告)号：EP4154877A1

公开(公告)日：2023-03-29

申请号：EP21809755.8

申请日：2021-03-05

申请人： OSAKA UNIVERSITY

发明人： HIRANO Ken-ichi

IPC分类号： A61K31/23 ,  A23L2/52 ,  A23L33/10 ,  A23L33/115 ,  A61P9/00 ,  A61P9/10

摘要： The present invention provides an agent for inducing regression of triglyceride (TG) deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, an agent for improving blood flow in a patient with TG deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, and a pharmaceutical or food or drink product comprising the agent for inducing regression of TG deposit atherosclerosis or the agent for improving blood flow.

公开(公告)号：EP3981468A1

公开(公告)日：2022-04-13

申请号：EP20826284.0

申请日：2020-06-19

申请人： Kinki University ,  Yashiro Co., Ltd. ,  Osaka University

发明人： ZAIMA Nobuhiro ,  KUGO Hirona ,  KITANO Motohiro ,  HIROTA Yoshinori ,  HIRANO Ken-ichi

IPC分类号： A61P9/14 ,  A61K31/20

摘要： An aortic aneurysm has few noticeable symptoms and is at high risk for rupture without a sign of abnormality. Further, if it ruptures, it causes a shock state due to massive blood loss and results in a very low survival rate. Thus, when the aortic aneurysm is found by physical examination or the like, a surgery with a stent graft or the like needs to be performed according to the state of its progression.
A pharmaceutical composition for preventing an aortic aneurysm including a medium chain fatty acid as a main component has an effect of inhibiting the occurrence and progression of the aortic aneurysm. Thus, when the aortic aneurysm is found, the composition through continuous intake can exhibit effects including inhibition of the progression of the aortic aneurysm and improvement in the vital prognosis.